PARP1 and cancer: However, many patients without apparent HR defects also respond well to PARP inhibitor and cisplatin treatment.5,6 Thus, it is extremely important to develop strategies to precisely identify these patients who will benefit from such therapies, and to understand the mechanism by which these drugs kill cancer cells to design more effective therapy.